INTRODUCTION
Heparan sulfate proteoglycans are abundant molecules in the extracellular matrix and cell surface, consisting of a proteoglycan core protein attached to heparan sulfate chains 1. Heparan sulfate chains are composed of alternating N-acetylglucosamine and glucuronic acid moieties. The fine structure of the heparan sulfate chains are modified through a series of enzymatic reactions 1. Heparan sulfate serves as a docking site for multiple chemokines, lipids, and growth factors 2, 3. We hypothesized that the fine structure of the heparan sulfate chain influenced proliferative properties of the VSMC. This hypothesis was based on previous findings in transgenic models in which heparan sulfate modifying enzymes had been deleted resulting in altered proliferation of different cell types 4–11.
Expression of one of the many heparan sulfate modifying enzymes, Ndst1, is up-regulated 40 fold in response to vascular injury 12. Ndst1 catalyzes an initial step in heparan sulfate modification - replacing N-acetyl groups with sulfate on the N-acetylglucoasamine residues 1, 13. We utilized two cre recombinase mouse models to delete Ndst1 in smooth muscle to test the role of Ndst1 in vascular remodeling. The two promoters used to express cre recombinase in smooth muscle were SM22α and SMMHC. The SM22α-cre+Ndst1−/− mouse exhibited efficient and specific loss of Ndst1 in smooth muscle. As previously described in the literature 14, the SMMHC-cre+Ndst1−/− mouse exhibited ectopic recombination of floxed alleles in the germline and less efficient expression of cre-recombinase in smooth muscle compared to the SM22α promoter. Although loss of a single allele in the germline and less efficient deletion in smooth muscle in the SMMHC-cre+Ndst1−/− was not a fatal flaw, this model was limited to initial studies. Compromised Ndst1 expression led to significantly reduced lesion formation in response to injury in both models. Additional studies in the targeted SM22α-cre+Ndst1−/− lines showed a 50% loss of VSMC and decreased size of the femoral artery that was evident at day 7 which persisted through till adulthood. These findings may have important implications for the role of heparan sulfate in vascular structure and remodeling.
MATERIALS AND METHODS
Generation of Ndst1 deficient mouse models
Ndst1 deficient mice Ndst1flox/flox mice were mated with male SM22α-cre mice (gift from Dr. M. Parmacek). F1 cre+Ndst1wt/flox males were mated with Ndst1flox/flox females to generate mice with smooth muscle specific deletion of Ndst1. Ndst1flox/flox mice were also backcrossed to a line of transgenic mice expressing Cre recombinase under the control of the smooth muscle heavy chain promoter (SMMHC-cre) 15 (gift from Dr. M. Kotlikoff). This mating resulted in whole body deletion of one floxed allele of Ndst1 and loss of Ndst1 in smooth muscle. The phenotype resulting from mating with this line of SMMHC-cre mice has been characterized 14, 16. Genotype of the control mice used for the study was cre− Ndst1+/+.
The following primers were used to genotype the Ndst1flox, Ndst1wt and Ndst1−/− alleles: Ndst1 (1–10R) 5′ccagggcgtcagggcctcctg-3′, Ndst1 (1–16R) 5′-catcctctgaggtgaccgc3′, Ndst1 (1–17F) 5′-tcccacatggcgagactgaggttc-3 8. Ndst1+/+t and Ndst1flox alleles were identified by primer pair 1–10R and 1–17F while Ndst1−/− allele was genotyped using 1–16R and 1–17F. Mice harboring deleted Ndst1 allele were also genotyped for Cre using primers: 5′ ccaatttactgaccgtacacc-3′; 5′-gtttcactatccaggttacgg-3′} 15.
HPLC analysis of heparan sulfate disaccharide
Aorta were harvested from 16–20 weeks old males from all the cohorts and total heparan sulfate were isolated and profiled by HPLC according to the protocol described in Toyoda et al 17. In brief, heparan sulfate isolated from each sample was enzymatically digested with a heparan lyase mixture into disaccharides. The disaccharides were then separated by reverse-phase ion-pairing HPLC, which allows for the quantification of six distinct disaccharide species. These include one unsulfated disaccharide, Δ4,5-uronic acid-N-acetylglucosamine (D0A0), two monosulfated disaccharides: Δ4,5-uronic acid-N-sulfated glucosamine (D0S0) and Δ4,5-uronic acid-N-acetylglucosamine-6-O-sulfate (D0A6), two disulfated disaccharides: Δ4,5-uronic acid-N-sulfoglucosamine-6-O-sulfate (D0S6), and 2-O sulfated Δ4,5-uronic acid-N-sulfoglucosamine (D2S0), and one trisulfated disaccharide: 2-O sulfated Δ4,5-uronic acid-N-sulfoglucosamine-6-O-sulfate (D2S6). The classification of unsaturated disaccharides is described in Lawrence et al 18.
Assessment of Hemodynamic and Vascular Function
Mice were induced and maintained using isoflurane. Mice (n=4 in each cohort) were ventilated and the chest was opened to expose the heart. Following the removal of the pericardium and volume calibration procedures, a 1.2 Fr PV catheter (Scisense) inserted into the left ventricle via a stab incision in the apex of the heart. Following the surgical interventions, isoflurane was reduced to 1% for the functional measurements of baseline hemodynamics.
Surgical Intervention to induce Vascular Lesion
Animals were anaesthetized and all surgical procedures were in accordance with institutional IACUC guidelines and best practices for small animal surgery. A straight guide wire (0.38 mm in diameter) was inserted into the left femoral artery of 16–20 weeks old male mice via a small muscular branch as previously described 19–21. The wire was left in the lumen for 1 minute to denude and dilate the artery. After removing the wire the small branch was tied off and blood flow was restored in the injured vessel.
Morphometry
Mice were perfused with PBS followed by 10% neutral-buffered Formalin using the, “In Vivo Rodent Perfusion System”(Automate Scientific). Morphometric evaluation along the length of femoral arteries harvested at 0 and 28 days post injury was performed by staining 5 μm paraffin embedded sections with hematoxylin-eosin (H&E) and examination under an Olympus BX41 microscope. Equally spaced sections (8–10 per mouse), covering 500 μm of femoral artery length were measured for Internal Elastic Lamina (IEL), External Elastic Lamina (EEL) lengths, for lumen, for intimal and medial areas. Sections of femoral arteries from all the cohorts were also stained with Verhoeff-Van Gieson stain for better visualization of IEL and EEL. All the measurements were done using the NIH ImageJ software. Morphometric analyses of newborn pups were done as mentioned above.
Immunohistochemistry
Immunohistochemical localization of N-sulfated epitopes on native HS chains was performed on 5 μm sections of injured and non-injured femoral arteries. Three randomly chosen sections per animal were stained for N-sulfated epitopes by using 5 ug/mL of anti-mouse HS-10E4 (Seikagaku, Japan) as previously described 22. Anti-mouse HS-10E4 specifically recognizes an epitope containing an N-sulfated residue in native HS chains. Staining intensity in femoral artery section was measured by using Photoshop 7.0. The intensity was plotted as a ratio of brown stained area pixels to total intimal area pixels. For quantification of collagen content 5μm sections of femoral arteries 28 days post injury from all the cohorts were stained for Masson’s Trichrome staining. Collagen content was quantified by using Photoshop 7.0 and plotted as a ratio of blue stained pixels to total intimal area pixels. VSMCs were counted following staining with anti Smooth Muscle α-actin (Sigma).
Western Analysis
Aortas from control, SMMHC-cre+Ndst1−/− and SM22α-cre+Ndst1−/− mice were lysed in RIPA buffer containing protease inhibitors. Tissue or VSMC lysates were run on a 10% gel and Ndst1 protein was detected with anti-Ndst1 N20 antibody (Santa Cruz Biotechnology). Anti-mouse β-actin (Sigma-Aldrich) was used a loading control.
Cell Proliferation
Cell proliferation 3 days post injury in femoral arteries was assessed by Bromodeoxyuridine (BrdU) incorporation according to the manufacturer’s instructions (Roche). Control and SM22α-cre+Ndst1−/− mice were injured as previously described 19–21 and harvested three days post injury. One hour prior to sacrifice, mice were injected with BrdU (ip, 1–2mL/100 g body weight). Sections were processed according to the manufacturer’s instructions. Proliferating VSMC in neonatal femoral arteries was assessed by staining with Ki67 (Thermo Scientific). Cells were visualized following secondary staining with anti rabbit Alexa fluor 594 (Invitrogen). Proliferating VSMCs in vitro were assessed with [3H]-Thymidine as previously described 23. Briefly, A7r5 VSMC were treated with 75 mM sodium chlorate or vehicle in the presence of 10% serum for 24 hours, [3H]-Thymidine (1.0 mCi/ml) was added for the last four hours.
Real Time quantitative PCR
RNA was extracted from tissues and VSMCs using the RNeasy kit (Qiagen) and reverse transcribed to cDNA (Advantage RT-PCR, BD Biosciences). Real Time quantitative PCR utilizing Applied Biosystems primer probe protocol was performed with the following targets: Ndst1 (Mm01262753_m1), Ndst2 (Mm00447818_m1), Ndst3 (Mm00453178_m1), Ndst4 (Mm00480767_m1), HPRT1 (Mm01545399_m1). All target gene expressions were normalized to HPRT1, an internal control. HPRT expression was unchanged between models. Analysis was performed in the ABI7900. Gene expression was calculated using the delta delta Ct method as previously reported 24.
Isolation and culturing of aortic VSMCs was done according to the protocol described in Ray et al 25.
Statistical Analysis
All values are represented as mean ± SE. Statistical significance compared to cre−Ndst1+/+ control values was analyzed by one-way ANOVA. A value of p<0.05 was considered statistically significant.
RESULTS
The goals of this study were to determine the role of heparan sulfate modification on VSMC proliferation, vessel size and vascular remodeling in response to injury in neonatal and adult mice. To do this we utilized two genetic models with deleted expression of Ndst1.
The two murine models are described in the Materials and Methods section. Briefly, the SM22α-cre+Ndst1−/− mouse exhibits targeted loss of Ndst1 in smooth muscle. The SMMHC-cre+Ndst1−/− mouse exhibits a single allele of Ndst1 throughout all tissues and decreased expression of Ndst1 in smooth muscle. Transcript abundance of Ndst1 was decreased in femoral arteries of the SMMHC-cre+Ndst1−/− and SM22α-cre+Ndst1−/− mice (Figure 1a). Ndst1 transcript levels in isolated VSMCs was decreased in SMMHC-cre+Ndst1−/− and SM22α-cre+Ndst1−/− compared to cre−Ndst1+/+ mice (Online Figure IA). Ndst1 protein in SM22α-cre+Ndst1−/− aorta and in isolated VSMCs from SMMHC-cre+Ndst1−/− was also decreased compared to controls (Figure 1b). Disaccharide profiles performed with HPLC provide a functional measurement of loss of function of Ndst1 in mouse aorta. The SM22α-cre+Ndst1−/− mice exhibited the most significant loss of N- and 2-O sulfation (3.6 fold and 4.5 fold, respectively). Comparatively, the SMMHC-cre+Ndst1−/− mice exhibited a 2 fold decrease in N- and a 1.5 fold decrease in 2-O sulfation (Figure 1c). A cartoon diagram of a native heparan sulfate chain and a heparan sulfate chain generated in the absence of Ndst1 is shown for comparison in Figure 1d. Note the loss of N-sulfated residues spaced throughout the length of the chain. Immunostaining for N-sulfated epitopes provides a second means for detecting loss of Ndst1 in the vessel. Using the well-characterized antibody HS-10E4 22, which stains N-sulfated epitopes, we confirmed the significant loss of N-sulfated heparan sulfate epitopes in vessels from both models (Online Figure IB-D). Quantification of the staining intensities is shown in Online Figure IE. Note, the transcript abundance of Ndst2 did not change with loss of Ndst1 (control 0.30 ± 0.04 (n=7); SMMHC-cre+Ndst1−/− 0.37 ± 0.07 (n=3); SM22α-cre+Ndst1−/− 0.26 ± 0.03 (n=3)). Ndst3 and 4 expressions were undetectable, as we have previously reported 12.
Figure 1.
Characterization of Ndst1 deficient mouse models. (a) Ndst1 transcript abundance in adult femoral arteries of control, SMMHC-cre+Ndst1−/− and SM22α-cre+Ndst1−/− mice (n=5/group) as normalized to HPRT1. The control mice used in this experiment and throughout the study were cre−Ndst1+/+. (b) Western analysis of Ndst1 protein in aorta from (1) SM22α-cre+Ndst1−/−, (2) control, (3) SMMHC-cre+Ndst1−/− and in VSMC from (4) control and (5) SM22α-cre+Ndst1−/−. (c) Heparan sulfate disaccharide analysis of Ndst1 deficient mouse models. Bars represent mean ± SE of percent total sulfated, N-sulfated, 2-O sulfated, and 6-O sulfated disaccharides in aortae from control (n = 6), SMMHC-cre+Ndst1−/− (n=2) and SM22α-cre+Ndst1−/− (n = 3) mice. (d) Schematic representation of a native sulfated heparan sulfate chain and the loss of N-sulfated disaccharides as a result of cre mediated deletion of Ndst1. The heparan sulfate chains are depicted using standard symbol nomenclature. Dashed lines represent the disaccharide units generated by heparinases, which are then separated according to the number and pattern of sulfate groups.
To assess the consequence of the loss of smooth muscle Ndst1 on the functional characteristics of the heart hemodynamic measurements were performed in SM22α-cre+Ndst1−/− mice. Systolic pressure and Left Ventricular End-diastolic Pressure (LVEDP) were not significantly different in SM22α-cre+Ndst1−/− mice (Figure 2a and b). In addition, ejection fraction (control 37 ± 3.5; SM22α-cre+Ndst1−/− 46 ± 8, p=ns) was not altered at baseline in SM22α-cre+Ndst1−/− (n=4) compared to age matched controls (n=4).
Figure 2.
Heart function is not altered in Ndst1 deficient mice (a) Systolic pressure and (b) LVEDP were not significantly different at baseline in SM22α-cre+Ndst1−/− mice (n=4) as compared to control mice (n=4, p=ns). Remaining heart function data is within the text. (d) Medial cell number is significantly reduced in neonatal and adult SM22α-cre+Ndst1−/− mice. Bars represent mean ± SE of SMα-actin positive medial nuclei from sections of neonatal femoral artery from control (n=5) and SM22α-cre+Ndst1−/− (n=4) and adult femoral arteries from control (n=6) and SM22α-cre+Ndst1−/− mice (n=5) (e) Proliferation in neonatal SM22α-cre+Ndst1−/− femoral arteries (n=4) compared to control (n=3). Sections were stained with anti-Ki67 and anti-SMα-actin. Bars represent mean ± SE of Ki67 positive VSMC out of total number of VSMC in femoral arteries from both cohorts.
Histomorphological evaluation of femoral arteries from neonatal and adult SM22α-cre+Ndst1−/− mice revealed decreased lumen area of the vessels, and reduced length of both the IEL and EEL as compared to controls (Table 1). The number of VSMCs in the neonatal and adult femoral arteries showed a ~ 50% decrease in SM22α-cre+Ndst1−/− mice (Figure 2c). Proliferating VSMCs were significantly reduced in SM22α-cre+Ndst1−/− neonatal femoral arteries compared to control femoral arteries (Figure 2d). Proliferating VSMCs were not detected in femoral arteries of adult mice. No change in VSMC number or vessel size was seen in the adult SMMHC-cre+Ndst1−/− mice (data not shown). This coincided with the increased expression of Ndst1 mRNA and N- and 2-O-sulfated disaccharides compared to the SM22α-cre+Ndst1−/− mice as shown in Figures 1a and b.
Table 1.
Morphometry of femoral arteries from neonatal and adult mice. Measurements were performed on H&E stained sections of femoral arteries (5 sections per mouse) using the NIH ImageJ software. Sections were stained with Verhoeff’s Elastin stain for better visualization of EEL and IEL. Values are Mean ± SE. p values are compared to control.
| Measurements | Neonatal mice | Adult mice | ||
|---|---|---|---|---|
| Control (n=5) | SM22α-cre+Ndst1−/− (n=4) | Control (n=6) | SM22α-cre+Ndst1−/− (n=4) | |
| Medial Area (mm2) | 5.847 × 10−3 ± 0.001 | 3.312 ×10−3 ± 0.001 (p=0.002) | 1.462 × 10−2 ± 0.008 | 1.193 × 10−2 ± 0.005 (p=NS) |
| Lumen area (mm2) | 3.805 ×10−3 ± 0.001 | 2.830 ×10−3 ± 0.001 (p=0.005) | 3.482 × 10−2 ± 0.005 | 1.592 × 10−2 ± 0.002 (p=0.02) |
| IEL (mm) | 0.368 ± 0.010 | 0.280 ± 0.014 (p=0.006) | 0.805 ± 0.024 | 0.659 ± 0.021 (p=0.02) |
| EEL (mm) | 0.390 ± 0.012 | 0.305 ± 0.013 (p=0.006) | 0.889 ± 0.034 | 0.779 ± 0.021 (p=0.02) |
To study the effect of Ndst1 deletion in vascular remodeling, a well-characterized wire injury was performed 19–21. At 28 days post injury, the intima/media ratio was decreased in both SM22α-cre+Ndst1−/− and SMMHC-cre+Ndst1−/− mice compared to control mice (Figure 3a-d). The intimal area in both the models was significantly reduced in response to injury. Detailed morphometry measurements in both the models are listed in Table 2. To test the hypothesis that loss of N-sulfated disaccharides inhibited VSMC proliferation in response to injury, BrdU incorporation assays were performed. Three days post injury, BrdU incorporation in medial VSMCs was decreased by 50% in SM22α-cre+Ndst1−/− mice compared to control mice (Figure 3e). In parallel, in vitro Inhibition of sulfation decreased proliferation in rat embryonic smooth muscle cells (Figure 3f).
Figure 3.
Loss of Ndst1 decreases intima/media ratio in response to vascular injury in femoral artery in adult mice. (a–c) Representative photomicrographs of femoral arteries 28 days post injury with Verhoeff-Van Gieson staining in control, SMMHC-cre+Ndst1−/− and SM22α-cre+Ndst1−/− mice. Scale bar = 25μm. (d) Histogram depicting morphometry measurements of intima/media ratios from control (n=9), SMMHC-cre+Ndst1−/− (n=9) and SM22α-cre+Ndst1−/− (n=5) femoral arteries 28 days post injury. (e) In vivo assessment of cell proliferation by BrdU incorporation. BrdU incorporation was significantly reduced in SM22α-cre+Ndst1−/− (n=3) as compared to control mice (n=4) 3 days post vascular injury. (f) in vitro inhibition of sulfation decreases proliferation of rat embryonic smooth muscle cells.
Table 2.
Morphometric measurements of femoral arteries in response to injury. 5μm sections of femoral arteries at 28 days post injury were stained with H&E and digitized. Sections were stained with Verhoeff’s Elastin stain for better visualization of EEL and IEL. All the measurements were performed using NIH ImageJ. Values are mean ± SE and p values are compared to control.
| Measurements | Control (n=9) | SMMHC-cre+Ndst1−/− (n=9) | SM22α-cre+Ndst−/− (n=5) |
|---|---|---|---|
| Lumen area (mm2) | 0.018 ± 0.002 | 0.019 ± 0.002 | 0.015± 0.003 |
| Intimal area (mm2) | 0.040 ± 0.003 | 0.023 ± 0.002 (p=0.001) | 0.024 ± 0.002 (p=0.006) |
| Medial area (mm2) | 0.016 ± 0.001 | 0.017 ± 0.001 | 0.014 ± 0.001 |
| Intima/Media ratio | 2.640 ± 0.048 | 1.369 ± 0.164 (p=0.001) | 1.86 ± 0.197 (p=0.004) |
| EEL (mm) | 0.998 ± 0.022 | 0.910 ± 0.023 | 0.819 ± 0.047 (p=0.05) |
| IEL (mm) | 0.898 ± 0.018 | 0.829 ± 0.023 | 0.724 ± 0.047 (p=0.001) |
Quantification of the staining intensity of N-sulfated epitopes was significantly reduced in the lesion from the SM22α-cre+Ndst1−/− as compared to control mice (Online Figure II). In addition, collagen was also decreased in both the models compared to control mice (Figure 4a–c). Quantification of the loss of collagen content in the lesion in SMMHC-cre+Ndst1−/− and SM22α-cre+Ndst1−/− mice is depicted in Figure 4d.
Figure 4.
(a–c) Representative photomicrographs of femoral arteries 28 days post injury with Masson’s Trichrome staining in control, SMMHC-cre+Ndst1−/− and SM22α-cre+Ndst1−/− mice. Scale bar = 25μm. (d) Ndst1 deficiency leads to reduced collagen content in the intima in response to injury. Bars represent mean ± SE of collagen content in femoral arteries from control (n=6) SMMHC-cre+Ndst1−/− (n=6) and SM22α-cre+Ndst1−/− (n=5) mice at 28 days post injury.
DISCUSSION
We utilized two genetic mouse models; SMMHC-cre+Ndst1−/− and SM22α-cre+Ndst1−/− to study the role of Ndst1 in vascular remodeling. Both the models exhibited significant reduction in N- and 2-O-sulfated disaccharide species along the heparan sulfate chain. In response to injury both the models showed significantly smaller lesions in association with reduced collagen content. Vessels of SM22α-cre+Ndst1−/− which showed a greater loss of N- and 2-O sulfated disaccharides exhibited a ~ 50% reduction in VSMC number and proliferation. In this study we provide new evidence that the level of N- and 2-O sulfation of heparan sulfate is critical in the regulation of VSMC proliferation and determination of vessel size.
Heparan sulfate serves as a docking site for multiple chemokines, lipids, and growth factors 2, 3, yet its function is often overlooked. The pathobiology of diseases including atherosclerosis and diabetes has been associated with alterations in heparan sulfate proteoglycans 26–28. The fine structure of heparan sulfate is modified by a number of enzymatic reactions 1, 29–31. How the fine structure of heparan sulfate influences tissue structure and risk of disease is a newly recognized area in biology. New data presented in this study suggests that N- and 2-O sulfated disaccharides contribute to VSMC proliferation, vessel size and vascular remodeling in response to injury. Heparan sulfate proteoglycans have been shown to serve as co-receptors for Wnt ligands 3. Earlier work from our laboratory demonstrated a role for β-catenin and Tcf-4 (Tcf7l2) in vascular remodeling 23. The Wnts involved in vascular remodeling have remained elusive. Ongoing studies in our laboratory are focused on the role of Wnt/Heparan sulfate signaling in vascular development and remodeling.
Systemic deletion of Ndst1 results in perinatal lethality characterized by severe developmental defects of the forebrain, eyes and lung 4, 5, 8. Disaccharide profiling of Ndst1 knockouts have demonstrated a similar decrease in N- and 2-O sulfated disaccharides 32. In the present study we utilize a sensitive HPLC technique to separate the specific disaccharide profile and show a ~ 4-fold decrease in N- and 2-O sulfated disaccharides in the SM22α-cre+Ndst1−/− mice. This specific disaccharide profile was associated with a reduction in proliferating VSMC and decreased vessel size in neonatal and adult mice. The SMMHC-cre+Ndst1−/− mouse showed a ~ 1.5-fold decrease in N- and 2-O sulfated disaccharides. These mice did not show a decrease in VSMC number or vessel size. In this study we provide new evidence that N- and 2-O sulfation of heparan sulfate is critical in the regulation of VSMC proliferation and determination of vessel size. These findings confirm previously published work in other tissues/organs showing decreased cell proliferation in brain, endothelium, and bone of mice lacking Ndst1 33, 34.
Early studies demonstrated that purified and exogenous administration of heparin, a highly sulfated heparan sulfate; inhibit migration and proliferation of VSMC in response to vascular injury 35–39. In addition, PI-88 a heparan sulfate mimetic also suppressed VSMC proliferation in response to injury by binding FGF2 and blocking cellular signaling 7. Tran et al demonstrated increased VSMC proliferation in transgenic mice harboring a heparan sulfate deficient perlecan in response to injury 40. Baker et al. recently reported that overexpression of heparanase which cleaves heparan sulfate chains resulted in increased medial thickness and an increased lesion in response to injury 41. The data presented in this study provide evidence that modification of heparan sulfate fine structure, such that N and 2-O sulfation is significantly reduced in VSMC, results in a significant decrease in proliferating VSMCs and decrease in vessel size in neonatal mice. Taken together, these findings all suggest that heparan sulfate chains regulate VSMC proliferation. This is the first study to identify early changes in VSMC proliferation and vessel size as a result of specific modifications in heparan sulfate chains.
In summary, this study adds a new perspective to the current view of the role of heparan sulfate fine structure in vascular biology. In this study, we show that modification of the disaccharides on the heparan sulfate chains (loss of N- and 2-O sulfation) is sufficient to decrease VSMC proliferation, vessel size and the response to remodeling.
Supplementary Material
Acknowledgments
This work was partially funded by American Heart Association Post doctoral grant to NA (0520071Z), an RO1 award to J.D.E (HL57345), and an R01 to JLH (NIH-R01HL081715). A special thanks to the staff of the Histology Core facility, Lillehei Heart Institute, Jerry Sedgewick in the Biomedical Image Processing Lab, and Cynthia Dekay and Ken Stern for their help in the preparation of this manuscript.
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
References
- 1.Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem. 2002;71:435–71. doi: 10.1146/annurev.biochem.71.110601.135458. [DOI] [PubMed] [Google Scholar]
- 2.Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729–777. doi: 10.1146/annurev.biochem.68.1.729. [DOI] [PubMed] [Google Scholar]
- 3.Bishop JR, Schuksz M, Esko JD. Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature. 2007;446:1030–1037. doi: 10.1038/nature05817. [DOI] [PubMed] [Google Scholar]
- 4.Fan G, Xiao L, Cheng L, Wang X, Sun B, Hu G. Targeted disruption of NDST-1 gene leads to pulmonary hypoplasia and neonatal respiratory distress in mice. FEBS Lett. 2000;467:7–11. doi: 10.1016/s0014-5793(00)01111-x. [DOI] [PubMed] [Google Scholar]
- 5.Ringvall M, Ledin J, Holmborn K, van Kuppevelt T, Ellin F, Eriksson I, Olofsson AM, Kjellen L, Forsberg E. Defective heparan sulfate biosynthesis and neonatal lethality in mice lacking N-deacetylase/N-sulfotransferase-1. J Biol Chem. 2000;275:25926–30. doi: 10.1074/jbc.C000359200. [DOI] [PubMed] [Google Scholar]
- 6.Forsberg E, Kjellen L. Heparan sulfate: lessons from knockout mice. J Clin Invest. 2001;108:175–80. doi: 10.1172/JCI13561. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Francis DJ, Parish CR, McGarry M, Santiago FS, Lowe HC, Brown KJ, Bingley JA, Hayward IP, Cowden WB, Campbell JH, Campbell GR, Chesterman CN, Khachigian LM. Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88: phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation. Circ Res. 2003;92:e70–7. doi: 10.1161/01.RES.0000071345.76095.07. [DOI] [PubMed] [Google Scholar]
- 8.Grobe K, Inatani M, Pallerla SR, Castagnola J, Yamaguchi Y, Esko JD. Cerebral hypoplasia and craniofacial defects in mice lacking heparan sulfate Ndst1 gene function. Development. 2005;132:3777–86. doi: 10.1242/dev.01935. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Kinnunen T, Huang Z, Townsend J, Gatdula MM, Brown JR, Esko JD, Turnbull JE. Heparan 2-O-sulfotransferase, hst-2, is essential for normal cell migration in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2005;102:1507–1512. doi: 10.1073/pnas.0401591102. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Pan Y, Woodbury A, Esko JD, Grobe K, Zhang X. Heparan sulfate biosynthetic gene Ndst1 is required for FGF signaling in early lens development. Development. 2006;133:4933–4944. doi: 10.1242/dev.02679. [DOI] [PubMed] [Google Scholar]
- 11.Pallerla SR, Pan Y, Zhang X, Esko JD, Grobe K. Heparan sulfate Ndst1 gene function variably regulates multiple signaling pathways during mouse development. Dev Dyn. 2007;236:556–563. doi: 10.1002/dvdy.21038. [DOI] [PubMed] [Google Scholar]
- 12.Adhikari N, Rusch M, Mariash A, Li Q, Selleck SB, Hall JL. Alterations in Heparan Sulfate in the Vessel in Response to Vascular Injury in the Mouse. J Cardiovasc Transl Res. 2008;1(3):236–240. doi: 10.1007/s12265-008-9047-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Kirkpatrick CA, Selleck SB. Heparan sulfate proteoglycans at a glance. J Cell Sci. 2007;120:1829–1832. doi: 10.1242/jcs.03432. [DOI] [PubMed] [Google Scholar]
- 14.Frutkin AD, Shi H, Otsuka G, Levéen P, Karlsson S, Dichek DA. A critical developmental role for tgfbr2 in myogenic cell lineages is revealed in mice expressing SM22-Cre, not SMMHC-Cre. J Mol Cell Cardiol. 2006;41:724–731. doi: 10.1016/j.yjmcc.2006.06.067. [DOI] [PubMed] [Google Scholar]
- 15.Xin HB, Deng KY, Rishniw M, Ji G, Kotlikoff MI. Smooth muscle expression of Cre recombinase and eGFP in transgenic mice. Physiol Genomics. 2002;10:211–215. doi: 10.1152/physiolgenomics.00054.2002. [DOI] [PubMed] [Google Scholar]
- 16.Lepore JJ, Cheng L, Min Lu M, Mericko PA, Morrisey EE, Parmacek MS. High-efficiency somatic mutagenesis in smooth muscle cells and cardiac myocytes in SM22alpha-Cre transgenic mice. Genesis. 2005;41:179–184. doi: 10.1002/gene.20112. [DOI] [PubMed] [Google Scholar]
- 17.Toyoda H, Kinoshita-Toyoda A, Fox B, Selleck SB. Structural analysis of glycosaminoglycans in animals bearing mutations in sugarless, sulfateless, and tout-velu. Drosophila homologues of vertebrate genes encoding glycosaminoglycan biosynthetic enzymes. J Biol Chem. 2000;275:21856–21861. doi: 10.1074/jbc.M003540200. [DOI] [PubMed] [Google Scholar]
- 18.Lawrence R, Lu H, Rosenberg RD, Esko JD, Zhang L. Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat Methods. 2008;5:291–292. doi: 10.1038/nmeth0408-291. [DOI] [PubMed] [Google Scholar]
- 19.Basi DL, Adhikari N, Mariash A, Li Q, Kao E, Mullegama SV, Hall JL. Femoral artery neointimal hyperplasia is reduced after wire injury in Ref-1+/− mice. American Journal of Physiology. 2007;292:H516–21. doi: 10.1152/ajpheart.00246.2006. [DOI] [PubMed] [Google Scholar]
- 20.Wang X, Li Q, Adhikari N, Hall JL. A role for muscle LIM protein (MLP) in vascular remodeling. J Mol Cell Cardiol. 2006;40:503–509. doi: 10.1016/j.yjmcc.2006.01.005. [DOI] [PubMed] [Google Scholar]
- 21.Sata M, Maejima Y, Adachi F, Fukino K, Saiura A, Sugiura S, Aoyagi T, Imai Y, Kurihara H, Kimura K, Omata M, Makuuchi M, Hirata Y, Nagai R. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by reproducible neointimal hyperplasia. J Mol Cell Cardiol. 2000;32:2097–104. doi: 10.1006/jmcc.2000.1238. [DOI] [PubMed] [Google Scholar]
- 22.David G, Bai XM, Van der Schueren B, Cassiman JJ, Van den Berghe H. Developmental changes in heparan sulfate expression: in situ detection with mAbs. J Cell Biol. 1992;119:961–75. doi: 10.1083/jcb.119.4.961. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Wang X, Xiao Y, Mou Y, Zhao Y, Blankesteijn WM, Hall JL. A Role for the {beta}-Catenin/T-Cell Factor Signaling Cascade in Vascular Remodeling. Circ Res. 2002;90:340–347. doi: 10.1161/hh0302.104466. [DOI] [PubMed] [Google Scholar]
- 24.Prokunina-Olsson L, Welch C, Hansson O, et al. Tissue-specific alternative splicing of TCF7L2. Hum Mol Genet. 2009;18:3795–3804. doi: 10.1093/hmg/ddp321. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Ray JL, Leach R, Herbert JM, Benson M. Isolation of vascular smooth muscle cells from a single murine aorta. Methods Cell Sci. 2001;23:185–188. doi: 10.1023/a:1016357510143. [DOI] [PubMed] [Google Scholar]
- 26.Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417:750–754. doi: 10.1038/nature00804. [DOI] [PubMed] [Google Scholar]
- 27.Williams KJ, Liu M, Zhu Y, Davidson WR, McCue P, Sharma K. Loss of Heparan N-Sulfotransferase in Diabetic Liver. Diabetes. 2005;54:1116–1122. doi: 10.2337/diabetes.54.4.1116. [DOI] [PubMed] [Google Scholar]
- 28.Nadanaka S, Kitagawa H. Heparan Sulphate Biosynthesis and Disease. J Biochem. 2008;144:7–14. doi: 10.1093/jb/mvn040. [DOI] [PubMed] [Google Scholar]
- 29.Lindahl U, Kusche-Gullberg M, Kjellen L. Regulated diversity of heparan sulfate. J Biol Chem. 1998;273:24979–82. doi: 10.1074/jbc.273.39.24979. [DOI] [PubMed] [Google Scholar]
- 30.Selleck SB. Proteoglycans and pattern formation: sugar biochemistry meets developmental genetics. Trends Genet. 2000;16:206–212. doi: 10.1016/s0168-9525(00)01997-1. [DOI] [PubMed] [Google Scholar]
- 31.Esko JD, Lindahl U. Molecular diversity of heparan sulfate. J Clin Invest. 2001;108:169–73. doi: 10.1172/JCI13530. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Ledin J, Staatz W, Li JP, Gotte M, Selleck SB, Kjellen L, Spillmann D. Heparan sulfate structure in mice with genetically modified heparan sulfate production. J Biol Chem. 2004;279:42732–41. doi: 10.1074/jbc.M405382200. [DOI] [PubMed] [Google Scholar]
- 33.Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 2005;5:526–542. doi: 10.1038/nrc1649. [DOI] [PubMed] [Google Scholar]
- 34.Fuster MM, Wang L, Castagnola J, Sikora L, Reddi K, Lee PH, Radek KA, Schuksz M, Bishop JR, Gallo RL, Sriramarao P, Esko JD. Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J Cell Biol. 2007;177:539–549. doi: 10.1083/jcb.200610086. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature. 1977;265:625–626. doi: 10.1038/265625a0. [DOI] [PubMed] [Google Scholar]
- 36.Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration. Circ Res. 1986;58:839–45. doi: 10.1161/01.res.58.6.839. [DOI] [PubMed] [Google Scholar]
- 37.Lindner V, Karnowsky MJ, Clowes AW, Reidy MA. Inhibition of smooth muscle cell proliferation in injured rat arteries. Interaction of heparin with basic fibroblast growth factor. J Clin Invest. 1992;90:2044–9. doi: 10.1172/JCI116085. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Majesky M, Schwartz S, Clowes M, Clowes A. Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Circ Res. 1987;61:296–300. doi: 10.1161/01.res.61.2.296. [DOI] [PubMed] [Google Scholar]
- 39.Bingley JA, Hayward IP, Campbell JH, Campbell GR. Arterial heparan sulfate proteoglycans inhibit vascular smooth muscle cell proliferation and phenotype change in vitro and neointimal formation in vivo. Journal of Vascular Surgery. 1998;28:308–318. doi: 10.1016/s0741-5214(98)70167-3. [DOI] [PubMed] [Google Scholar]
- 40.Tran P, Tran-Lundmark K, Soininen R, Tryggvason K, Thyberg J, Hedin U. Increased Intimal Hyperplasia and Smooth Muscle Cell Proliferation in Transgenic Mice With Heparan Sulfate-Deficient Perlecan. Circ Res. 2004;94:550–558. doi: 10.1161/01.RES.0000117772.86853.34. [DOI] [PubMed] [Google Scholar]
- 41.Baker AB, Groothuis A, Jonas M, Ettenson DS, Shazly T, Zcharia E, Vlodavsky I, Seifert P, Edelman ER. Heparanase Alters Arterial Structure, Mechanics, and Repair Following Endovascular Stenting in Mice. Circ Res. 2009;104:380–387. doi: 10.1161/CIRCRESAHA.108.180695. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.




